NCT05854784View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP)

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 28, 2023

Primary Completion Date

December 28, 2023

Study Completion Date

December 28, 2023

Conditions
Variegate Porphyria
Interventions
DRUG

Afamelanotide 16 MG

Eligible patients will receive one dose of afamelanotide 16mg every 28 days (up to six doses), as a controlled-release formulation.

Trial Locations (1)

Unknown

CLINUVEL investigational site, Rotterdam

Sponsors
All Listed Sponsors
lead

Clinuvel Pharmaceuticals Limited

INDUSTRY